| Zugriffe | |
|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 130 |
| März 2025 | April 2025 | Mai 2025 | Juni 2025 | Juli 2025 | August 2025 | September 2025 | |
|---|---|---|---|---|---|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 2 | 0 | 0 | 5 | 14 | 0 | 0 |
| Zugriffe | |
|---|---|
| 2020_Philipp_etal.pdf | 161 |
